Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis

Abstract Background Tolvaptan slows kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD) who are at risk of rapid progression. Given that treatment requires commitment to long-term use, we evaluated the effects of tolvaptan discontinuation on the trajectory o...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Michael Lioudis, Xiaolei Zhou, Eric Davenport, Sasikiran Nunna, Holly B. Krasa, Dorothee Oberdhan, Ancilla W. Fernandes
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2023-06-01
Edice:	BMC Nephrology
Témata:	Autosomal dominant polycystic kidney disease (ADPKD) Tolvaptan Glomerular filtration rate Kidney volume Clinical trial Treatment
On-line přístup:	https://doi.org/10.1186/s12882-023-03247-6
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!